Elanco Animal Health (NYSE:ELAN) Hits New 52-Week High – Time to Buy?

Elanco Animal Health Incorporated (NYSE:ELAN) shares reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $23.17 and last traded at $23.0150, with a volume of 1331305 shares traded. The stock had previously closed at $22.25.

Analyst Ratings Changes

ELAN has been the topic of several recent analyst reports. UBS Group raised their target price on Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. KeyCorp began coverage on Elanco Animal Health in a research note on Friday. They issued an “overweight” rating and a $27.00 price target on the stock. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Finally, JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.56.

Elanco Animal Health Trading Up 3.8%

The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The stock has a market cap of $11.48 billion, a P/E ratio of 384.98, a P/E/G ratio of 3.02 and a beta of 1.71. The company has a 50-day moving average price of $20.87 and a two-hundred day moving average price of $17.11.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the business posted $0.13 earnings per share. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. lifted its position in shares of Elanco Animal Health by 26.8% during the 1st quarter. Envestnet Asset Management Inc. now owns 268,791 shares of the company’s stock valued at $2,822,000 after buying an additional 56,887 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Elanco Animal Health by 138.8% in the 1st quarter. Victory Capital Management Inc. now owns 271,338 shares of the company’s stock worth $2,849,000 after buying an additional 157,708 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Elanco Animal Health in the 1st quarter worth about $5,699,000. Kovack Advisors Inc. increased its stake in Elanco Animal Health by 14.2% during the 1st quarter. Kovack Advisors Inc. now owns 16,060 shares of the company’s stock worth $169,000 after buying an additional 2,000 shares in the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of Elanco Animal Health by 7.2% during the first quarter. Cetera Investment Advisers now owns 33,234 shares of the company’s stock valued at $349,000 after acquiring an additional 2,230 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.